Last updated: February 16, 2024
Sponsor: Dr. Falk Pharma GmbH
Overall Status: Active - Recruiting
Phase
2
Condition
Liver Disease
Treatment
norUrsodeoxycholic acid
Clinical Study ID
NCT05083390
NUT-3/NAS
Ages 18-74 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Must be willing to participate in the study and provide written informed consent
- Male or female patients ≥ 18 and < 75 years
- Centrally assessed histological evidence of NASH and liver fibrosis
- Women of childbearing potential agree to use a highly effective method of birthcontrol during the entire duration of the trial and for 4 weeks following the lastdose of trial treatment
Exclusion
Exclusion Criteria:
- Patients taking prohibited medications
- Presence of liver cirrhosis
- Type 1 diabetes or uncontrolled Type 2 diabetes
- History or presence of any other significant concomitant liver diseases
- History of liver transplantation
- BMI >45 kg/m^2
- Any known relevant infectious disease (e.g., active tuberculosis, acquiredimmunodeficiency syndrome [AIDS]-defining diseases)
- Abnormal renal function (glomerular filtration rate estimated from cystatin C < 30ml/min) at screening visit
- Any active malignant disease (except for basal cell carcinoma)
- Existing or intended pregnancy or breast-feeding
Study Design
Total Participants: 363
Treatment Group(s): 1
Primary Treatment: norUrsodeoxycholic acid
Phase: 2
Study Start date:
July 08, 2019
Estimated Completion Date:
April 30, 2025
Connect with a study center
Medical University of Vienna, Department of Internal Medicine III
Vienna,
AustriaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.